Bypassing Damaged Eyes: Dutch Startup Prepares Brain Implant to Restore Sight
Amsterdam, Friday, 23 October 2026.
Phosphoenix secured fresh funding to ready clinical trials for a brain implant using over 1,000 electrodes and AI, bypassing damaged eyes to generate artificial sight directly in the brain.
Engineering an Artificial Visual Pathway
Classified within the rapidly advancing healthtech and medical technology (medtech) sector, Phosphoenix is engineering neuroprosthetic solutions designed to circumvent irreversible ocular trauma [1][4]. Under standard physiological conditions, visual perception occurs as light captured by the eye travels through the retina and along the optic nerve into the brain for processing [1]. When profound trauma or degenerative disease destroys the retina or optic nerve, this biological communication line is severed, leaving roughly 40 million individuals worldwide living with severe blindness without effective restorative treatment options [1]. Phosphoenix overcomes this biological bottleneck by bypassing the optical organs entirely, delivering engineered visual inputs directly into deeper cerebral processing centers [1].
The Mechanism Behind the Fountain Probe
At the core of the Dutch startup’s neuroprosthetic platform is the Fountain Probe™, a proprietary intracortical interface developed to stimulate the brain directly [1]. The implant features more than 1,000 micro-electrodes calibrated to transmit targeted electrical impulses into a dedicated visual subcortical relay, the lateral geniculate nucleus (LGN) [1]. Integrated with artificial intelligence algorithms that translate real-world visual scenes into neuroelectrical sequences, these micro-stimulations generate phosphenes—localized points of light that can be consciously perceived by the patient [1]. By orchestrating arrays of these phosphenes simultaneously, the system constructs artificial visual patterns [1].
Restoring Independence and Functional Vision
The principal clinical and social benefit of this neuroprosthetic technology lies in its capacity to restore functional vision to patients who have developed severe or complete blindness later in life [1]. By enabling users to distinguish structural outlines, basic shapes, and moving objects, the device aims to re-establish essential navigational capabilities and environmental awareness [1][2]. According to Sara Schaafsma, investment manager at regional development agency ROM InWest, restoring these sensory faculties offers patients increased self-reliance, potentially diminishing their dependence on constant external care and enabling fuller social and civic participation [1].
Institutional Roots and Leadership in Amsterdam
Phosphoenix traces its scientific foundation directly to the Netherlands Institute for Neuroscience (Nederlands Instituut voor Neurowetenschappen), firmly rooting the company’s operations and laboratory development in Amsterdam [1]. The company is guided by Chief Executive Officer Hans Brons, alongside key scientific and operational leaders including Pieter Roelfsema, Bert Monna, Mick Valentin, and Jenny Tsin [2][4]. The startup’s €1.3 million financing round brings together regional and specialized life sciences investors, including ROM InWest, Innovatiefonds Noord-Holland, the FIRST Fund managed by BioGeneration Ventures, and the TTT Medtech Fund managed by 819 Capital Partners [1][4].
Capital Roadmap Toward Clinical Trials
The secured €1.3 million capital infusion directly funds the accelerated preparatory phase required for Phosphoenix’s scheduled First-in-Human (FIH) clinical study in 2027, executed in collaboration with the Amsterdam UMC academic medical center [1][4]. In tandem with clinical protocol validation and regulatory submissions for its neurostimulation system, management is advancing negotiations for a planned Series A funding round targeting approximately €20 million [1]. Securing that subsequent round would represent a funding expansion of 18.7 million euros above the current bridge round, providing the necessary operational runway to execute human trials [1].
Neurotechnology Investment Climate in Late 2026
Phosphoenix’s milestone coincides with a broader surge of capital into clinical neurotechnology and healthtech ventures in late 2026 [3][4]. Major industry bellwethers have demonstrated substantial liquidity, exemplified by Precision Neuroscience’s $250 million Series D funding round in September 2026 to scale thin-film electrode interfaces, and OrbiMed’s closure of $3 billion across two dedicated healthcare private equity vehicles in mid-October 2026 [3][4]. As specialized medtech platforms across Europe—such as glucose sensor maker Sava securing $36 million in Series B financing—attract institutional backing, Phosphoenix’s targeted approach demonstrates the transition of neural interfaces from theoretical academic research into regulated clinical application [4][7].